vcr - conversation today

Summary of discussion with VCR today

Ventracor is in the process of planning the upcoming CE trials including working on ways to explain to the market its competitive landscape.

Included in this will be the profiling of similar companies trying to commercialise medical devices and other technologies.

VCR is aware that another transplant would be well received by the market and is dedicated to ensuring this will occur asap but with consideration given to ensuring they get quality results rather than quantity.

VCR has committed to meeting the deadline and winding up enrolment in current pilot trial. The delays in the trial are not related to issues of safety, but investigators want to find the right patients and scheduling them and making sure that they are good candidates for the device.

Current CEO Colin Sutton has enormous device experience, he is working very hard, almost the last one to leave everyday, and very focused on internal fundamental business issues and getting hospitals signed up.

At the recent Heart and Lung Conference there was strong interest in the device and VCR will inform shareholders shortly of any developments.

Recently CEO bought some additional stock with his own money (not a gift from the board or options).